Hirano Y, Fujihira S, Ohara K, Katsuki S, Noguchi H
Toxicology Research Laboratories, Fujisawa Pharmaceutical Company, Osaka, Japan.
Transplantation. 1992 Apr;53(4):889-94. doi: 10.1097/00007890-199204000-00033.
FK506, a new immunosuppressant, caused glucose intolerance in rats given daily oral doses of 1, 5, or 10 mg/kg/day for 14 days, but did not induce hyperglycemia under normal feeding. Besides the glucose intolerance, insulin secretion was impaired and insulin levels in the pancreas were lowered. Histopathologically, there was vacuolation of the Langerhans islets in the animals given 10 mg/kg. After withdrawal of the drug, these changes in pancreatic function and morphology returned to normal within 2 weeks. The findings indicate that FK506 caused dose-dependent but reversible islet toxicity in rats.
新型免疫抑制剂FK506,在大鼠连续14天每日口服1、5或10毫克/千克/天剂量后会导致葡萄糖不耐受,但在正常喂养条件下不会诱发高血糖。除葡萄糖不耐受外,胰岛素分泌受损,胰腺中的胰岛素水平降低。组织病理学检查显示,给予10毫克/千克剂量的动物的胰岛出现空泡化。停药后,胰腺功能和形态的这些变化在2周内恢复正常。这些发现表明,FK506在大鼠中引起剂量依赖性但可逆的胰岛毒性。